Washington, Apr 18 (ANI): A new nasal delivery technology with fluticasone, developed by OptiNose, has been found effective in treating chronic rhinosinusitis in a Phase II trial.
Chronic rhinosinusitis (CRS) is a common disease that severely reduces a patient's quality of life, and has few effective treatments currently available.
OptiNose's breath-actuated, bi-directional nasal delivery technology significantly improves delivery to the target sites deep into the nose where the openings to the sinuses are located, which is considered essential to achieving clinical effects in CRS with topical treatments.
The study was conducted at the AMC in Amsterdam, Holland with Professor Wytske Fokkens as the principal investigator.
The researchers found that patients in the active treatment group experienced significant improvements in nasal symptoms, nasal discomfort and sense of smell.
The patients also reported a highly significant and progressive reduction in nasal swelling.
By using the OptiNose delivery device, patients self-administered fluticasone propionate 400 ug or placebo twice-daily at home over a 12-week period.
After the endoscopic assessment of the nasal mucosa, the researchers found a highly significant and progressive improvement to a normal state in the actively treated group.
At the post-study examination, 30 percent had a normal ENT-examination and peak nasal inspiratory flow and rhinosinusitis outcome measures were also significantly improved.
MR imaging before and after treatment showed significant improvement compared to baseline.
"We are extremely pleased with the effectiveness of our treatment for chronic rhinosinusitis", said ENT-specialist Dr. Per Djupesland, the study's co-author.
The study was presented at the Rhinology World conference in Philadelphia. (ANI)